Type I IFNs Decrease SARS-CoV-2 Replication in Human Cardiomyocytes and Increase Cytokine Production in Macrophages

I型干扰素可降低SARS-CoV-2在人类心肌细胞中的复制,并增加巨噬细胞中的细胞因子产生。

阅读:10
作者:Verónica Durán # ,Eirini Nikolouli # ,Shambhabi Chatterjee # ,Bibiana Costa ,Andreas Pavlou ,Annett Ziegler ,Jennifer Becker ,Kira Baumann ,Matthias Bruhn ,Kathrin Haake ,Anna Rafiei Hashtchin ,Ingrid Gensch ,Andrea Korte ,Yvonne Lisa Behrens ,Shen-Ying Zhang ,Jean-Laurent Casanova ,Christian Bär ,Nico Lachmann # ,Thomas Thum # ,Ulrich Kalinke #

Abstract

The cellular basis of COVID-19 severity in patients with deficiencies in type I IFN immunity remains unclear. In this study, we differentiated cardiomyocytes and macrophages from IFNAR1 competent (IFNAR1comp) and deficient (IFNAR1def) induced pluripotent stem cells (iPSCs), and analyzed virus replication and cytokine production after exposure to SARS-CoV-2. Cardiomyocytes expressed the SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) and showed abundant SARS-CoV-2 replication, which was higher in IFNAR1def than IFNAR1comp cells. Treatment with exogenous IFNα mitigated infection in IFNAR1comp, but not in IFNAR1def cardiomyocytes. In contrast, macrophages did not express ACE2 and did not support SARS-CoV-2 replication, but produced pro-inflammatory cytokines upon virus exposure, which was impaired in IFNAR1def macrophages. In conclusion, type I IFNs decrease SARS-CoV-2 replication in human iPSC-derived cardiomyocytes, while they increase cytokine responses of macrophages.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。